Tian Zhang: Always enjoy seeing Toni Choueiri top 10 GU papers of the year
Tian Zhang, Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center, shared a post by Toni Choueiri, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), on X, adding:
“Always enjoy seeing Toni Choueiri top 10 GU papers of the year!
2024 banner year for EV-pembro in bladder, OS benefit of adj pembro in RCC, and ALLIANCE for Clinical Trials in Oncology AMBASSADOR adj pembro improved DFS in bladder. TiNivo2 negative also informs Tivo use in RCC.
Let’s keep moving the needle!”
Quoting Toni Choueiri’s post:
“IT IS THIS TIME OF THE YEAR AGAIN!
TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024
– PFS benefit: 12.5 vs 6.3 mo (HR= 0.45)
– OS benefit: 31.5 vs 16.1 mo (HR= 0.47).
Tom Powles, ESMO2023 Plenary.”
Tian Zhang is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center. She specializes in the diagnosis and treatment of genitourinary malignancies. She has gained an international reputation developing clinical trials in kidney, prostate, and bladder cancers.
She serves as the study chair for PDIGREE, a phase III trial in metastatic renal cell carcinoma. She serves on numerous committees, including as Co-chair of the National Cancer Institute Genitourinary (GU) Steering Committee Renal Task Force and as Chair of the Chinese American Hematologist and Oncologist Network (CAHON) Academic Committee.
She is a member of several ASCO clinical management guidelines committees as well as the Alliance for Clinical Trials in Oncology, GU Oncology, and Immuno-Oncology Committees. She has received multiple peer-reviewed grants, a Resident Research Mentoring Award from Duke, and, notably, the 2021 Cancer Prevention and Research Institute of Texas (CPRIT) Scholar Rising Stars Award.
Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.
As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023